First-in-Human Study of the Pharmacokinetics and Antiviral Activity of IDX375, a Novel Nonnucleoside Hepatitis C Virus Polymerase Inhibitor

Eitemau Tebyg

• Single-Dose Escalation and Multiple-Dose Safety, Tolerability, and Pharmacokinetics of IDX899, a Candidate Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Subjects
  gan: Zhou, Xiao-Jian, et al.
  Cyhoeddwyd: (2009)
• Safety and Pharmacokinetics of IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor of Hepatitis C Virus, in Healthy Subjects
  gan: Zhou, Xiao-Jian, et al.
  Cyhoeddwyd: (2011)
• Short-Term Monotherapy with IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor, in Patients with Chronic Hepatitis C Virus Infection
  gan: Lalezari, Jacob, et al.
  Cyhoeddwyd: (2012)
• Antiviral Activity of MK-4965, a Novel Nonnucleoside Reverse Transcriptase Inhibitor
  gan: Lai, Ming-Tain, et al.
  Cyhoeddwyd: (2009)
• Antiviral Activity of GW678248, a Novel Benzophenone Nonnucleoside Reverse Transcriptase Inhibitor
  gan: Ferris, Robert G., et al.
  Cyhoeddwyd: (2005)